Sponsored Content
- Sponsored Content
- Manufacturing
Moving Beyond PEI: Improved Transfection Processes for AAV and LV Manufacture
BPI Contributor
May 25, 2022
20 Min View
Date: May 25, 2022
Duration: 20 Min
Already have an account?
Sponsored by Mirus Bio
GMP-compliant nucleic acid delivery to HEK 293 cells is often a critical first step in the manufacture of advanced therapies, utilizing recombinant adeno-associated virus (AAV) or lentivirus (LV) to facilitate delivery of a therapeutic transgene to patients. Accordingly, the need for safe and reproducible large-scale viral vector manufacture processes has never been greater.
Mirus Bio has developed a fully synthetic, innovative transfection formulation to enable higher titer AAV and LV generation and reduce the cost of therapeutic development and manufacture to bring more life-changing doses to patients sooner.
Key takeaways:
Optimization strategies for achieving higher AAV and LV titers via transient transfection workflows in both adherent and suspension HEK 293 cells.
Key considerations for reagent selection and process development for a seamless transition from R&D scale to commercial manufacturing.
How VirusGEN® GMP AAV and LV products enable significantly higher functional titers than PEI-derived polymers or liposomes alone.
Just fill out the form below to watch the recorded webcast now.
About the Author
You May Also Like
Sponsored Content
Jun 5 - Jun 6, 2024
Jun 5 - Jun 6, 2024
Exploit Advances in Exosomes to Improve Efficiencies in Drug Delivery: Connect with senior-level executives and scientists who will share new data and novel case studies on advancing EV products through clinical stage towards commercialization
Learn More
